These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 7612698)

  • 21. H-40, an antigen controlled by an Igh-linked gene and recognized by cytotoxic T lymphocytes. II. Recognition of H-40 as a tumor antigen in leukemic animals.
    Henderson LA; Ciavarra R; Riblet R; Forman J
    J Immunol; 1984 Nov; 133(5):2778-85. PubMed ID: 6434638
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term protection against human papillomavirus e7-positive tumor by a single vaccination of adeno-associated virus vectors encoding a fusion protein of inactivated e7 of human papillomavirus 16/18 and heat shock protein 70.
    Zhou L; Zhu T; Ye X; Yang L; Wang B; Liang X; Lu L; Tsao YP; Chen SL; Li J; Xiao X
    Hum Gene Ther; 2010 Jan; 21(1):109-19. PubMed ID: 19715402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
    Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
    Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Simian virus 40 large-T-antigen-specific rejection of mKSA tumor cells in BALB/c mice is critically dependent on both strictly tumor-associated, tumor-specific CD8(+) cytotoxic T lymphocytes and CD4(+) T helper cells.
    Utermöhlen O; Schulze-Garg C; Warnecke G; Gugel R; Löhler J; Deppert W
    J Virol; 2001 Nov; 75(22):10593-602. PubMed ID: 11602701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rejection of tumors in mice with severe combined immunodeficiency syndrome determined by the major histocompatibility complex. Class I expression on the graft.
    Glas R; Waldenström M; Höglund P; Klein G; Kärre K; Ljunggren HG
    Cancer Res; 1995 May; 55(9):1911-6. PubMed ID: 7728758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Eliciting protective immune responses against murine myeloma challenge in lymphopenia mice through adoptive transfer of tumor antigen-specific lymphocytes and immunization of tumor vaccine secreting mIL-21.
    Dou J; Wu Y; Wang J; Zhao F; Chu L; Liu C; Wen P; Hu W; Hu K; He XF; Gu N
    Cancer Gene Ther; 2010 Oct; 17(10):675-83. PubMed ID: 20539320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. B7-1 expression decreases tumorigenicity and induces partial systemic immunity to murine neuroblastoma deficient in major histocompatibility complex and costimulatory molecules.
    Katsanis E; Xu Z; Bausero MA; Dancisak BB; Gorden KB; Davis G; Gray GS; Orchard PJ; Blazar BR
    Cancer Gene Ther; 1995 Mar; 2(1):39-46. PubMed ID: 7542553
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
    Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
    Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A retrogen strategy for presentation of an intracellular tumor antigen as an exogenous antigen by dendritic cells induces potent antitumor T helper and CTL responses.
    You Z; Hester J; Rollins L; Spagnoli GC; van der Bruggen P; Chen SY
    Cancer Res; 2001 Jan; 61(1):197-205. PubMed ID: 11196161
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
    Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
    Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lack of correlation between rejection of tumor cells co-expressing interleukin-2 and B7.1 and vaccine efficiency.
    Cayeux S; Richter G; Becker C; Beck C; Aicher A; Pezzutto A; Dörken B; Blankenstein T
    Eur J Immunol; 1997 Jul; 27(7):1657-62. PubMed ID: 9247574
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Specificity and longevity of antitumor immune responses induced by B7-transfected tumors.
    Townsend SE; Su FW; Atherton JM; Allison JP
    Cancer Res; 1994 Dec; 54(24):6477-83. PubMed ID: 7527298
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of responses elicited by immunization with a Legionella species common lipoprotein delivered as naked DNA or recombinant protein.
    Yoon WS; Park SH; Park YK; Park SC; Sin JI; Kim MJ
    DNA Cell Biol; 2002 Feb; 21(2):99-107. PubMed ID: 11953009
    [TBL] [Abstract][Full Text] [Related]  

  • 34. CD40 ligand preferentially modulates immune response and enhances protection against influenza virus.
    Hashem AM; Gravel C; Chen Z; Yi Y; Tocchi M; Jaentschke B; Fan X; Li C; Rosu-Myles M; Pereboev A; He R; Wang J; Li X
    J Immunol; 2014 Jul; 193(2):722-34. PubMed ID: 24928989
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Persistent, antigen-specific, therapeutic antitumor immunity by dendritic cells genetically modified with an adenoviral vector to express a model tumor antigen.
    Song W; Tong Y; Carpenter H; Kong HL; Crystal RG
    Gene Ther; 2000 Dec; 7(24):2080-6. PubMed ID: 11223988
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumor-associated antigen/IL-21-transduced dendritic cell vaccines enhance immunity and inhibit immunosuppressive cells in metastatic melanoma.
    Aravindaram K; Wang PH; Yin SY; Yang NS
    Gene Ther; 2014 May; 21(5):457-67. PubMed ID: 24572790
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cutting edge: induction of enhanced CTL-dependent protective immunity in vivo by N-end rule targeting of a model tumor antigen.
    Tobery T; Siliciano RF
    J Immunol; 1999 Jan; 162(2):639-42. PubMed ID: 9916680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cell surface expression of heat shock protein gp96 enhances cross-presentation of cellular antigens and the generation of tumor-specific T cell memory.
    Dai J; Liu B; Caudill MM; Zheng H; Qiao Y; Podack ER; Li Z
    Cancer Immun; 2003 Jan; 3():1. PubMed ID: 12747743
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of a cloned ultraviolet radiation (UV)-induced suppressor T cell line that is capable of inhibiting anti-UV tumor-immune responses.
    Roberts LK
    J Immunol; 1986 Mar; 136(5):1908-16. PubMed ID: 2936813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24.
    Suzue K; Young RA
    J Immunol; 1996 Jan; 156(2):873-9. PubMed ID: 8543845
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.